Tracon raises $36M in a downsized IPO

Cancer drug developer Tracon Pharmaceuticals pulled in $36 million in an IPO, pricing well below its expected range as it works to get its top drug into late-stage trials. The San Diego biotech sold 3.6 million shares at $10 each, far off from its early plans of pricing between $12 and $14. With the proceeds, Tracon will fund the Phase II development of TRC105, an antibody that blocks a protein essential to the formation of new blood cells, thereby starving tumors and killing cancer. More

Suggested Articles

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.

The deal gives Sarepta exclusive licenses to four CNS targets plus an option to pay a further $42.5 million to add another four targets to the deal.

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.